The conference agenda addressed several topics, including updates on WHO's regulatory systems strengthening initiatives and the enlargement of scopes of prequalification to include medical devices. Participants also discussed strategies for building capacity within the regulatory framework of medical products in Iran, aligning with WHO's goal to enhance efficiency in access to quality healthcare for all.

Among the distinguished attendees were Dr. Mehdi Pirsalehi, Deputy Minister and Head of the Iran FDA, and Dr. Alireza Raeisi, Deputy Minister for Public Health, along with other key figures from the Iranian health sector.

Razi Vaccine & Serum Research Institute presented an insightful report on the institute’s manufacturing capabilities, recent advancements in medical products, and ongoing training initiatives. Discussions highlighted the institute's critical role in the eradication and control of medical diseases, emphasizing its impact on national health strategies.

According to the officials, the meeting is part of a collaborative effort between the Iran FDA and WHO aimed at improving regulatory structures and standardization and facilitating international processes in the medical field. This strategic dialogue is poised to advance Iran's health system and enhance the country's readiness to meet emerging public health challenges.

The contributions of Razi Institute underscored the institute's commitment to advancing healthcare in Iran and its vital role in the global pharmaceutical landscape.

It is noteworthy that the following representatives from Razi Institute attended this meeting: Dr. Ali Es-haghi, Director General; Dr. Masoud Ghader, Deputy of Quality Assurance; Dr. Ali Rezaei Mokarram, Medical Products Supervisor; and Dr. Rainak Ghaderi, Head of Academic Relations and International Affairs Office.